market-capitalisation
Philip Morris forecasts higher profits, shrugging off threats from rivals
Bitcoin slump shakes companies that jumped on crypto-hoarding bandwagon
Volkswagen overtook Tesla as Europe's top EV seller in 2025
Novo reports first Ozempic sales drop in greater China region
Vodafone on track for top-end profit though shares slip on German recovery
Date: February 5, 2026
LONDON, Feb 5 (Reuters) - Mobile group Vodafone on Thursday said top-line growth in Germany and a strong contribution from Turkey and Africa in its third quarter kept it on track to report full-year...
Analysis-Novo Nordisk risks weight-loss price war as discount pressures deepen
Date: February 4, 2026
By Maggie Fick, Jacob Gronholt-Pedersen and Bhanvi Satija LONDON, Feb 4 (Reuters) - Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as "...
Tesla UK sales plunge in January as Chinese rivals race ahead, New Automotive data shows
Date: February 4, 2026
Feb 4 (Reuters) - Tesla sold less than half the number of battery-electric vehicles recorded by Chinese rival BYD in the UK last month, data from New Automotive showed on Wednesday, pointing to...
Novo Nordisk plunge wipes $50 billion off obesity drug giant
Date: February 4, 2026
Feb 4 (Reuters) - Novo Nordisk shares tumbled 16% on Wednesday, wiping off around $50 billion from the Wegovy maker's market capitalization after it warned on Tuesday its sales and profits would fall...
Understanding the Factors Shaping Bitcoin’s Current Market Conditions
Date: February 4, 2026
Following Bitcoin’s sharp decline during Q4 2025, prices have shown signs of stabilization in early 2026, though the pace of recovery has remained gradual. Market observers note that a combination of macroeconomic developments, institutional positioning, and regulatory discussions continues to influence short-term market sentiment across digital assets. Traders and investors should closely monitor ...
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Date: February 3, 2026
Feb 3 (Reuters) - Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the...